Germany's Magna Diagnostics Heading Development of Point-of-Care Molecular Testing Platform

Magna is spearheading a public-private consortium to develop a point-of-care molecular testing platform based on magnetic nanoparticles and PCR amplification. Other partners in the consortium include the Fraunhofer Institute and Siemens.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.